iX Biopharma Ltd. Interim Results Analysis – 1H FY2026
iX Biopharma Ltd., a Singapore-listed specialty pharmaceutical and nutraceutical company, released its unaudited condensed interim financial statements for the six months ended 31 December 2025. Below is a detailed analysis of the company’s key financial metrics, business developments, and management commentary, with actionable insights for investors.
Key Financial Metrics & Year-Over-Year Comparison
| Metric |
1H FY2026
(Ended 31 Dec 2025) |
2H FY2025
(Ended 30 Jun 2025) |
1H FY2025
(Ended 31 Dec 2024) |
YoY Change |
QoQ Change |
| Revenue |
\$3.18m |
\$4.21m (inferred: previous half-year) |
\$3.71m |
-14% |
-24% (inferred) |
| Gross Profit |
\$0.82m |
\$0.83m (inferred: previous half-year) |
\$0.83m |
-1% |
-1% |
| Gross Margin |
26% |
22% |
22% |
+4pp |
+4pp |
| Net Loss |
\$(2.06)m |
\$(0.87)m (inferred: previous half-year) |
\$(6.25)m |
+67% (loss reduction) |
-137% (inferred: loss increase) |
| EPS (cents) |
-0.23 |
-0.10 (inferred) |
-0.72 |
+67% (loss reduction) |
-130% (inferred) |
| Dividend |
None |
None |
None |
– |
– |
| Cash & Equivalents |
\$5.8m |
\$0.9m |
\$1.5m |
+287% |
+544% |
Historical Performance Trends
The company posted a significant improvement in net loss, reducing it by 67% YoY from \$6.25m to \$2.06m. This was achieved despite a 14% drop in revenue, driven mainly by a steep decline in medicinal cannabis manufacturing sales (-36%), partially offset by a surge in nutraceutical sales (+170%). Gross margin improved from 22% to 26% due to favourable sales mix and cost management. Cash and cash equivalents rose sharply, reflecting successful fundraising and warrant exercises.
Exceptional Earnings and Expenses
- Currency exchange gains swung positive (\$1.28m vs. loss of \$2.60m last year).
- Impairment loss on receivables was minimal (\$0.03m).
- Fair value loss on convertible bonds was modest (\$0.03m vs. \$0.18m prior year).
- Expenses (excluding finance costs) were cut by 13% YoY, mainly by scaling back R&D and sales & marketing.
Chairman’s Statement
“The Company is focused on commercialising its wellness portfolio and expanding into compounding pharmacy channels in the United States (U.S.), backed by targeted R&D that delivers near-term monetizable opportunities. This disciplined approach shifts us away from traditional, long-cycle drug development and aligns innovation with clear commercial pathways.”
The tone is cautiously optimistic, emphasizing a shift to asset-light, monetizable opportunities and US market expansion.
Fundraising, Share Placements, and Dilution
- Private placement of 67m shares raised \$6.41m for US expansion, equipment, debt repayment, and working capital.
- Warrant conversions raised \$0.19m.
- Outstanding warrants (54.4m) may raise up to \$3.26m by July 2026, potentially diluting shareholders but improving liquidity.
Directors’ Remuneration
- Key management personnel compensation for 1H26: \$1.09m (wages, salaries, employee benefits, and share-based payments).
Macroeconomic & Industry Commentary
- US longevity and wellness markets are key growth engines, with SL-NAD+ positioned as a flagship product.
- Joint venture with Orion Specialty Labs (US FDA-registered 503B compounding facility) offers capital-light, rapid market entry.
- US compounding pharmacy market projected to grow rapidly (from \$6.3bn in 2024 to \$10.7bn by 2033), favouring iX’s technology.
- Risks: Geopolitical tensions, tariff uncertainty, and potential supply chain disruptions are acknowledged.
Dividend Policy
- No dividend declared or recommended for the current reporting period; cash is being conserved for product development and commercialization.
Related Party Transactions and Fund Flows
- No significant related party transactions outside of normal management compensation.
- No share buybacks. No treasury shares held.
Events and Corporate Actions
- Joint venture formation in the US could materially change revenue mix and growth trajectory.
- Asset-light expansion into US compounding pharmacies expected to accelerate commercialisation.
Financial Position Overview
- Net assets increased to \$4.13m from \$0.37m.
- Positive working capital position restored (\$0.43m vs. prior deficiency of \$4.77m).
- Liquidity strengthened; borrowings increased but manageable.
Conclusion and Recommendations
Overall, iX Biopharma Ltd. has delivered a markedly improved financial performance, reducing losses and strengthening its balance sheet, despite revenue headwinds. The company’s strategic pivot to asset-light, monetizable wellness products and expansion into the US compounding pharmacy market appears well-timed and could drive future growth. Cash reserves are healthy, and operational discipline is evident.
- If you are currently holding the stock: The improved financial metrics and positive outlook for US expansion suggest a hold position. The company is not yet profitable, but strategic execution and cash conservation are encouraging. Further upside may come from successful US market entry and warrant exercises.
- If you are not currently holding the stock: Consider monitoring for further signs of revenue growth and profitability, especially from US compounding pharmacy operations. Entry could be attractive if the joint venture delivers on its promise and loss reduction continues.
Disclaimer: This analysis is based strictly on information contained in the published interim financial report and does not constitute investment advice. Investors should consider their own risk tolerance and conduct additional due diligence.
View IX BiopharmaW260718 Historical chart here
